Pyrazolopyrimidines

Lancet

Volumn 358, Issue 9293, 2001, Pages 1623-1626

  George, C F P ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; HYPNOTIC SEDATIVE AGENT; PYRAZOLOPYRIMIDINE DERIVATIVE; RECEPTOR SUBUNIT; TRIAZOLAM; ZALEPLON; ZOLPIDEM; ZOPICLONE;

DRUG EFFECT; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; REVIEW; VERTIGO;

EID: 0035841617     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06656-9     Document Type: Review

References (38)

1. The direct economic costs of insomnia in the United States for 1995
2. B receptors in mammalian brain: Potential targets for drug development
3. GABA receptor mechanisms in the central nervous system
4. A receptor determined by electron microscopic image analysis
5. A receptor subtypes 1995
6. A receptors different from zolpidem, zopiclone and benzodiazepines
7. Comparative kinetics and dynamics of zaleplon, zolpidem and placebo
8. Zaleplon pharmacokinetics and absolute bioavailability
9. The safety and pharmacokinetics of zaleplon in hepatically impaired patients
10. The pharmacokinetics and safety of zaleplon in patients with renal impairment
11. Overview of drug-interactions with zaleplon
12. Analysis of potential drug interactions with zaleplon
13. Absence of an interaction between ibuprofen and zaleplon
14. Psychomotor effects of zaleplon and thioridazine coadministration
15. Efficacy and safety of 14 day administration of zaleplon 5 and 10 mg for the treatment of primary insomnia
16. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic: Zaleplon Clinical Study Group
17. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia
18. A 5 week polysomnographic assessment of zaleplon for the treatment of primary insomnia
19. Zaleplon is effective in reducing time to sleep onset
20. Improvement in sleep latency and sleep quality with zaleplon in elderly patient with primary insomnia
21. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia the Zaleplon Clinical Investigator Study Group
22. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects
23. A 28-night evaluation of the efficacy, next effects and withdrawal potential of zaleplon and zolpidem in out-patients with primary insomnia
24. Zaleplon: Dose response evaluation in primary insomnia
25. Safety and efficacy of zaleplon versus zolpidem in outpatients with chronic obstructive pulmonary disease (COPD) and insomnia
26. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance
27. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance
28. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia
29. The effects of single doses of CL284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers
30. A placebo controlled evaluation of single escalating dose of CL284,846, a non-benzodiazepine hypnotic
31. Comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening
32. Zaleplon and triazolam in humans: Acute behavioral effects and abuse potential
33. Evaluation of next day functioning and residual sedation in healthy subjects: Zaleplon vs flurazepam